AXGN to buy an FDA-cleared sutureless nerve repair for $200M cash
Axogen said it will acquire a differentiated, FDA-cleared sutureless nerve repair device. The $200M cash deal is expected to be accretive to revenue and margins in Year 1, with closing expected in Q4 2026.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.